T
Tomáš Vaňásek
Researcher at Charles University in Prague
Publications - 12
Citations - 765
Tomáš Vaňásek is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Ulcerative colitis & Crohn's disease. The author has an hindex of 5, co-authored 12 publications receiving 562 citations.
Papers
More filters
Journal ArticleDOI
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel,Remo Panaccione,Peter Bossuyt,Milan Lukas,Filip Baert,Tomáš Vaňásek,Ahmet Danalioglu,Gottfried Novacek,Alessandro Armuzzi,Xavier Hébuterne,Simon Travis,Silvio Danese,Walter Reinisch,William J. Sandborn,Paul Rutgeerts,Daniel W. Hommes,Stefan Schreiber,Ezequiel Neimark,Bidan Huang,Qian Zhou,Paloma Mendez,J Petersson,Kori Wallace,Anne M. Robinson,Roopal Thakkar,Geert R. D'Haens +25 more
TL;DR: This trial aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients management with a clinical management algorithm.
Journal ArticleDOI
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease
Satish Keshav,Tomáš Vaňásek,Yaron Niv,Robert Petryka,Stephanie Howaldt,Mauro Bafutto,István Rácz,D. J. Hetzel,Ole Haagen Nielsen,Severine Vermeire,Walter Reinisch,Per Karlén,Stefan Schreiber,Thomas J. Schall,Pirow Bekker +14 more
TL;DR: Encouraging results from this clinical trial led to initiation of Phase 3 clinical trials in Crohn’s disease.
Journal ArticleDOI
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
Remo Panaccione,Jean-Frederic Colombel,Simon Travis,Peter Bossuyt,Filip Baert,Tomáš Vaňásek,Ahmet Danalioglu,Gottfried Novacek,Alessandro Armuzzi,Walter Reinisch,Scott J. Johnson,Marric Buessing,Ezequiel Neimark,J Petersson,Wan-Ju Lee,Geert R. D'Haens +15 more
TL;DR: A TC strategy as used in the CALM trial is cost-effective compared with CM and incorporating costs related to work productivity increases the economic value of TC.
Journal ArticleDOI
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
Walter Reinisch,William J. Sandborn,Silvio Danese,Xavier Hébuterne,Maria Kłopocka,Dino Tarabar,Tomáš Vaňásek,Miloš Greguš,Paul Hellstern,Joo Sung Kim,Miles P. Sparrow,Kenneth J. Gorelick,Michael Hoy,Martina Goetsch,Caleb Bliss,Charu Gupta,Fabio Cataldi,Severine Vermeire +17 more
TL;DR: Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.
Journal ArticleDOI
Guidelines for the administration of biological therapy in patients with Crohn´s disease and ulcerative colitis: third updated edition
Martin Bortlik,Dana Ďuricová,Pavel Kohout,Michal Konečný,Jana Koželuhová,Aleš Novotný,Vladimír Zbořil,Lucie Prokopová,Tomáš Douda,Jiří Stehlík,Olga Shonová,Karel Mareš,Luděk Hrdlička,Petra Matějková,Zuzana Šerclová,Lenka Nedbalová,Marie Tomanová,Martin Liberda,Jiří Bronský,Katarina Mitrova,Pavel Drastich,Ondřej Ryska,Přemysl Falt,Jan Březina,Tomáš Vaňásek,Jaroslav Kalvach,Martin Kolář,Milan Lukáš +27 more